Drug Profile
Laropiprant/niacin/simvastatin
Alternative Names: MK-0524B; MK-524BLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperlipidaemics; Indoles; Naphthalenes; Nicotinic acids; Small molecules
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists; HMG-CoA reductase inhibitors; Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 01 Nov 2012 Discontinued - Phase-III for Hyperlipidaemia in Asia (PO)
- 01 Nov 2012 Discontinued - Phase-III for Hyperlipidaemia in Australia (PO)
- 01 Nov 2012 Discontinued - Phase-III for Hyperlipidaemia in Europe (PO)